|Nom||Titre||Payer||Exercé||Année de naissance|
|Ms. Malene Brondberg||Interim CEO & CFO||5,03M||S.O.||1973|
|Dr. Jostein Dahle Ph.D.||Co-Founder & Chief Scientific Officer||2,5M||S.O.||1973|
|Dr. Lars Nieba Ph.D.||Chief Technology Officer||4,95M||S.O.||1968|
|Dr. Gabriele Elbl Ph.D.||VP Global Regulatory Affairs||4,07M||S.O.||1961|
|Mr. Fredrik Haavind||Head of Legal & Compliance||S.O.||S.O.||S.O.|
|Ms. Maureen Deehan||Head of Corp. Devel. & Strategy||S.O.||S.O.||S.O.|
|Dr. Reza Safaei||Head of Medical Affairs||S.O.||S.O.||S.O.|
|Dr. Mark Wright||Head of Manufacturing||S.O.||S.O.||S.O.|
Nordic Nanovector ASA, a biopharmaceutical company, develops and commercializes therapeutics for hematological cancers in Norway. The company's lead product candidate is Betalutin, a CD37-targeting antibody-radionuclide-conjugate, which is in Phase 2b clinical trial for the treatment of patients with non-hodgkin lymphoma. Its preclinical development product also includes Alpha37, an anti-CD37 alphaparticle emitting radioimmunoconjugate for treating chronic lymphatic leukemia. The company has collaboration agreements with Paul Scherrer Institute; ArevaMed; LegoChem Bio; and Heidelberg Pharma. It also has a research collaboration with the University of Pennsylvania to generate a CD37-targeting CAR-T cell approach as a treatment for patients with B-cell malignancies. The company was formerly known as Nordic Nanovector AS and changed its name to Nordic Nanovector ASA in 2014. Nordic Nanovector ASA was incorporated in 2009 and is headquartered in Oslo, Norway.
L’ISS Governance QualityScore de Nordic Nanovector ASA en date du 1 novembre 2022 est 4. Les scores principaux sont Audit : 8; Société : 1; Droits des actionnaires : 1; Compensation : 8.